Clinical Trials Browser

Phase 2 × OTHER × bemarituzumab × Clear all

NCT06967987 2026-01-21

BEMAFLOT

Phase 2 Withdrawn

Adenocarcinoma

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Phase 2 Completed

80 enrolled 14 charts

Adenocarcinoma